Syngene Q1 FY27: Net loss Rs 9 cr, revenue down

What Syngene reported for the June 2026 quarter

Syngene International Ltd, a contract research and manufacturing services company, reported a consolidated net loss of Rs 9 crore for the quarter ended June 30, 2026. The result marked a sharp reversal from a consolidated net profit of Rs 86.7 crore in the corresponding quarter of the previous financial year. The company attributed the loss to lower revenue and termination benefits extended to employees, as disclosed in a regulatory filing. The update comes as investors track demand conditions across the research services and manufacturing outsourcing space. The June quarter is typically watched closely because it sets the tone for execution and pipeline conversion for the year.

Revenue fell year-on-year, reflecting a weaker quarter

Syngene’s revenue from operations for the quarter stood at Rs 736 crore, down from Rs 874.5 crore a year earlier. The decline in operating revenue was one of the key drivers behind the quarterly loss. While the filing did not provide segment-wise details in the provided text, the headline numbers indicate a meaningful contraction versus the base quarter. In contract research and manufacturing services, revenue swings can reflect project milestones, client ordering patterns, and capacity utilisation. The company’s disclosure highlighted revenue pressure alongside exceptional employee-related costs.

Expenses also declined, but not enough to offset the revenue drop

Total expenses for the quarter were reported at Rs 767 crore, compared with Rs 790.9 crore in the year-ago period. The reduction in expenses suggests some cost control, but the overall cost base remained above the revenue line, leading to the net loss. In a quarter where revenue falls sharply, the impact of relatively fixed costs can become more visible. The company’s filing specifically referenced the role of employee-related termination benefits booked during the period.

Termination benefits booked as an exceptional item

Syngene disclosed that, during the quarter ended June 30, 2026, it recognised an additional Rs 13.5 crore related to termination benefits. This was disclosed under “exceptional items”. Exceptional items are typically used to separately disclose costs that the company considers non-recurring or not reflective of underlying operating performance. While the filing text in the prompt does not provide further details on the nature or scale of employee actions, the disclosure makes clear that termination benefits were a material contributor to the quarterly result.

Board meeting and earnings call: what’s scheduled

Syngene said it will host its Q1 FY27 results conference call on Thursday, July 30, 2026, at 9:00 AM IST. The call follows a board meeting on Wednesday, July 29, 2026, where the company’s financial results for the quarter ended June 30, 2026, are to be considered and approved. These scheduled events matter because they are typically when management provides context on demand conditions, client activity, and the nature of any exceptional items. For investors, the Q&A can clarify whether the quarter reflects one-off issues or broader business trends.

Stock snapshot referenced in the update

The market snapshot included in the prompt showed Syngene shares quoted around Rs 439 to Rs 440, with gains of about 1.1% to 1.5% on the displayed updates. A separate “Today” reference showed Rs 433.65. The provided text does not specify whether these prints refer to the same trading session, and the timestamps shown are Tue, 30 Jun 2026 in the snapshot. Still, the figures indicate the stock trading in the mid-430s to 440 range in the referenced updates.

Key quarter numbers at a glance

Timeline of events disclosed

Longer-term financial context mentioned in the prompt

The prompt also included a multi-year summary of consolidated financials in INR million, which converts to INR crore at a rate of 10 million per crore. Using those figures, revenue from operations was Rs 3,738.7 crore in FY26 (37,387 million) compared with Rs 3,642.4 crore in FY25 (36,424 million). The table also showed FY26 EBITDA of Rs 989.2 crore (9,892 million) and an EBITDA margin of 26.0%, versus FY25 EBITDA of Rs 1,113.6 crore (11,136 million) and an EBITDA margin of 30.0%. Cash and cash equivalents at the end of FY26 were shown as Rs 228.6 crore (2,286 million), with a footnote stating cash and cash equivalents including investments in mutual funds and deposits at Rs 1,800.3 crore (18,003 million).

Why this quarter matters for investors

A swing from a profit to a loss, alongside a year-on-year revenue decline, raises immediate questions around project flow, client demand, and the extent to which cost actions are underway. The disclosed Rs 13.5 crore termination-benefit charge also signals organisational or operational changes that investors typically want explained in more detail. The upcoming board meeting and earnings call provide the next structured opportunity for the company to address the quarter’s drivers, including whether any costs were one-time in nature. Until then, the numbers show a quarter where lower revenue and exceptional employee costs outweighed the benefit of lower expenses.

Conclusion

Syngene’s June 2026 quarter ended with a Rs 9 crore consolidated net loss, as revenue from operations fell to Rs 736 crore and the company booked Rs 13.5 crore of termination benefits under exceptional items. The company’s board is scheduled to review and approve the unaudited financial statements on July 29, 2026, followed by the Q1 FY27 conference call on July 30, 2026 at 9:00 AM IST, where investors will look for added clarity on the factors behind the quarter.